USFDA gives nod to Alembic Pharma for Doxycycline Hyclate tablets

They should be considered in selecting or modifying anti-bacterial therapy.

86
USFDA
Picture: Pixabay

Last Updated on January 6, 2022 by The Health Master

Alembic Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for doxycycline hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg.

Alembic Pharma stated in a statement that the approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product Doryx tablets, 75 mg, 100 mg, 150 mg, and 200 mg, by Mayne Pharma International, stated Alembic Pharma in a statement.

Doxycycline hyclate delayed-release tablets are indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of other antibacterial drugs.

These tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying anti-bacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy, the statement said.

Doxycycline hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg have an estimated market size of USD 10 million for the twelve months ending September 2021, as per IQVIA.

USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules

USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection

USFDA gives nod to Granules India for Prazosin HCL capsules

USFDA gives nod to Lupin for this drug to treat Kidney disease

USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets

USFDA authorises first oral antiviral to treat COVID

DCGI directs all State Drugs Controllers to implement ONDLS portal

DTAB recommends Bar code on top 300 brands of drug products

CDSCO panel gives nod to Takeda Pharma for Vadolizumab

Take measures to avoid mixing-up of vaccines in 15-18 age group

These 13 Pharma Companies to launch Anti-COVID Drug Molnupiravir

DCGI gives nod to Serum India for developing jab against Omicron

Common ET Plant to help pharma firms to treat or reuse…

Pharma Firm booked for Rs 1,627 Crore Loan Fraud

Drug industry cheers FSSAI’s removal of ban on Methylcobalamin

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner